MAIA Biotechnology (MAIA) Proxy Filing summary

Executive summary

• Annual meeting scheduled for May 22, 2025, with virtual participation available for shareholders.

• Shareholders are encouraged to review proxy materials and vote by May 21, 2025, or May 19, 2025, for plan-held shares.

Voting matters and shareholder proposals

• Election of two Class III directors: Jean-Manassé Theagène and Stan V. Smith, both recommended by the board.

• Ratification of Grant Thornton LLP as independent registered public accounting firm for fiscal year ending December 31, 2025.

• Approval sought to amend the Certificate of Incorporation to increase authorized common stock from 70,000,000 to 150,000,000 shares.

• Provision to consider other business that may arise at the meeting or any adjournment.

Board of directors and corporate governance

• Board recommends all proposals, including director nominees and auditor ratification.